Plasma Prokineticin 1, a prognostic biomarker in colorectal cancer patients with curative resection: a retrospective cohort study

Tagai, Noriyuki; Goi, Takanori; Shimada, Masahiro; Kurebayashi, Hidetaka

doi:10.1186/s12957-021-02421-0

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it has been suggested that in colorectal cancers, PK1 functions as an important angiogenetic factor in both primary lesion and metastasis formation and may therefore be considered a possible CRC prognostic factor. A recent study demonstrated that plasma PK1 level may also be a potential predictive marker, especially in patients with advanced-stage CRC [80] (Figure 9). Also, PK2's role in CRC has been recently studied [81].…”

Section: Evidence Of the Pks In Gastrointestinal Tumorigenesis In Ibdsmentioning

confidence: 99%

“…From these evaluations, it emerged that in patients who did not express PK1 either in the plasma or at the level of the primary lesion, the mortality was 15.5%, in patients who expressed plasma PK1 the mortality rate was 25.7% (increase of 10.2%), while patients expressing PK1 in both plasma and primary tumors had a mortality of 40.7% (25.2% and 15% increase, respectively). These data have been edited and republished, in accordance with the specific editor copyright, by Tagai et al [80].…”

Section: Evidence Of the Pks In Gastrointestinal Tumorigenesis In Ibdsmentioning

confidence: 99%

See 1 more Smart Citation

The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview

Amodeo,

Franchi,

Galimberti

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) includes Crohn’s disease (CD) and ulcerative colitis (UC), which are characterized by chronic inflammation of the gastrointestinal (GI) tract. IBDs clinical manifestations are heterogeneous and characterized by a chronic relapsing-remitting course. Typical gastrointestinal signs and symptoms include diarrhea, GI bleeding, weight loss, and abdominal pain. Moreover, the presence of pain often manifests in the remitting disease phase. As a result, patients report a further reduction in life quality. Despite the scientific advances implemented in the last two decades and the therapies aimed at inducing or maintaining IBDs in a remissive condition, to date, their pathophysiology still remains unknown. In this scenario, the importance of identifying a common and effective therapeutic target for both digestive symptoms and pain remains a priority. Recent clinical and preclinical studies have reported the prokineticin system (PKS) as an emerging therapeutic target for IBDs. PKS alterations are likely to play a role in IBDs at multiple levels, such as in intestinal motility, local inflammation, ulceration processes, localized abdominal and visceral pain, as well as central nervous system sensitization, leading to the development of chronic and widespread pain. This narrative review summarized the evidence about the involvement of the PKS in IBD and discussed its potential as a druggable target.

show abstract

Section: Evidence Of the Pks In Gastrointestinal Tumorigenesis In Ibdsmentioning

confidence: 99%

Section: Evidence Of the Pks In Gastrointestinal Tumorigenesis In Ibdsmentioning

confidence: 99%

The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview

Amodeo,

Franchi,

Galimberti

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

Intermediate filament proteins are reliable immunohistological biomarkers to help diagnose multiple tissue‐specific diseases

Doğanyiğit

Eroğlu

Okan

2023

Anat Histol Embryol

View full text Add to dashboard Cite

Cytoskeletal networks are proteins that effectively maintain cell integrity and provide mechanical support to cells by actively transmitting mechanical signals. Intermediate filaments, which are from the cytoskeleton family and are 10 nanometres in diameter, are unlike actin and microtubules, which are highly dynamic cytoskeletal elements. Intermediate filaments are flexible at low strain, harden at high strain and resist breaking. For this reason, these filaments fulfil structural functions by providing mechanical support to the cells through their different strain‐hardening properties. Intermediate filaments are suitable in that cells both cope with mechanical forces and modulate signal transmission. These filaments are composed of fibrous proteins that exhibit a central α‐helical rod domain with a conserved substructure. Intermediate filament proteins are divided into six groups. Type I and type II include acidic and basic keratins, type III, vimentin, desmin, peripheralin and glial fibrillary acidic protein (GFAP), respectively. Type IV intermediate filament group includes neurofilament proteins and a fourth neurofilament subunit, α‐internexin proteins. Type V consists of lamins located in the nucleus, and the type VI group consists of lens‐specific intermediate filaments, CP49/phakinin and filen. Intermediate filament proteins show specific immunoreactivity in differentiating cells and mature cells of various types. Various carcinomas such as colorectal, urothelial and ovarian, diseases such as chronic pancreatitis, cirrhosis, hepatitis and cataract have been associated with intermediate filaments. Accordingly, this section reviews available immunohistochemical antibodies to intermediate filament proteins. Identification of intermediate filament proteins by methodological methods may contribute to the understanding of complex diseases.

show abstract

Therapeutic Potential of Targeting Prokineticin Receptors in Diseases

Vincenzi,

Kremić,

Jouve

et al. 2023

Pharmacol Rev

View full text Add to dashboard Cite

The prokineticins (PKs) were discovered approximately 20 years ago as small peptides inducing gut contractility. Today, they are established as angiogenic, anorectic, and proinflammatory cytokines, chemokines, hormones, and neuropeptides involved in variety of physiologic and pathophysiological pathways. Their altered expression or mutations implicated in several diseases make them a potential biomarker. Their G-protein coupled receptors, PKR1 and PKR2, have divergent roles that can be therapeutic target for treatment of cardiovascular, metabolic, and neural diseases as well as pain and cancer. This article reviews and summarizes our current knowledge of PK family functions from development of heart and brain to regulation of homeostasis in health and diseases. Finally, the review summarizes the established roles of the endogenous peptides, synthetic peptides and the selective ligands of PKR1 and PKR2, and nonpeptide orthostatic and allosteric modulator of the receptors in preclinical disease models. The present review emphasizes the ambiguous aspects and gaps in our knowledge of functions of PKR ligands and elucidates future perspectives for PK research. Significance Statement This review provides an in-depth view of the prokineticin family and PK receptors that can be active without their endogenous ligand and exhibits “constitutive” activity in diseases. Their non- peptide ligands display promising effects in several preclinical disease models. PKs can be the diagnostic biomarker of several diseases. A thorough understanding of the role of prokineticin family and their receptor types in health and diseases is critical to develop novel therapeutic strategies with safety concerns.

show abstract

Plasma Prokineticin 1, a prognostic biomarker in colorectal cancer patients with curative resection: a retrospective cohort study

Cited by 4 publications

References 27 publications

The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview

The Prokineticin System in Inflammatory Bowel Diseases: A Clinical and Preclinical Overview

Intermediate filament proteins are reliable immunohistological biomarkers to help diagnose multiple tissue‐specific diseases

Therapeutic Potential of Targeting Prokineticin Receptors in Diseases

Contact Info

Product

Resources

About